Mebendazole

Spectrum of antiparasitic action

The primary target for this drug is intestinal nematodiasis pathogens. The drug is characterized by a broad spectrum of activity against roundworms localized in the human digestive system.

Of particular value in medical practice is the drug's ability to affect mixed infections. In situations where a patient is infected with several types of parasites simultaneously (a condition defined in clinical parasitology as polyinfection), prescribing this agent avoids taking multiple narrow-spectrum drugs, ensuring comprehensive intestinal cleansing from various nematode species.

Pharmacokinetic features

The pharmacokinetic profile of the drug has distinct specificities that directly determine its clinical use and patient administration rules.

• Absorption and excretion: The overwhelming majority of the administered dose (over 90%) is not absorbed in the gastrointestinal tract at all. The drug substance remains directly in the intestinal lumen, where it exerts its anthelmintic effect on parasites. Afterward, the drug is eliminated from the body via feces in an absolutely unchanged form.
• Interaction with food: It is extremely important to consider the patient's diet during therapy. Consuming fatty foods radically alters pharmacokinetics: fats contribute to a sharp increase in the absorption of the active substance. This means that instead of a local effect in the intestine, the drug begins to penetrate the systemic circulation more actively, which is an undesirable effect.

Safety profile and adverse effects

Despite the fact that the bulk of the drug is normally not absorbed, a number of adverse reactions may develop during therapy. They can be divided into several clinical groups:

1. General systemic reactions: Patients may experience unmotivated fever, vomiting episodes, and severe headache.
2. Allergic and dermatological manifestations: Skin reactions in the form of pruritic rash are possible. Hair loss (alopecia) has been reported with high doses of the drug.
3. Hematological disorders: In the hematopoietic system, the drug can cause specific suppression of the leukocyte lineage, manifested as neutropenia (a pathological decrease in the number of neutrophils in peripheral blood).

Strict contraindications to prescription

Prescribing therapy requires a thorough medical history, as there are a number of conditions in which the use of this antinematodal agent is strictly prohibited:

• Intestinal ulceration: This is one of the most critical contraindications. When the integrity of the gastrointestinal mucosa is compromised, there is a serious risk of uncontrolled enhanced absorption of the drug into the systemic circulation, which significantly increases the likelihood of toxic effects.
• Liver pathologies: Any liver function impairments make the safe use of the drug impossible.
• Blood disorders: A diagnosed anemia in a patient is a direct limitation to starting therapy.
• Special life periods: The drug is strictly contraindicated during pregnancy and breastfeeding (lactation).
• Pediatric practice: In childhood, use is strictly limited — the drug is not prescribed to toddlers under two years of age.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Pathogenesis of alopecia development during the use of high doses of antinematodal agents
• Mechanisms of liver dysfunction against the background of systemic absorption of anthelmintic drugs
• Features of intestinal polyinfection therapy in pediatric practice in children over two years old
• The effect of dietary lipids on the pharmacokinetics of drugs with initially low bioavailability
• Hematotoxicity: mechanisms of neutropenia development during antiparasitic drug administration

Other topics in the "Drugs for protozoan infections" section

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.